Multiple Myeloma Clinical Trial
Official title:
Determination of the Efficacy and Feasibility of Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma – a Phase II Clinical Trial.
In vitro statins, inhibitors of the HMG-CoA-reductase, have been shown to overcome cell adhesion mediated drug resistance at very low concentrations. The purpose of the study is to investigate the in vivo efficacy of simvastatin as inhibitor of cell adhesion mediated drug resistance. Patients refractory to ongoing chemotherapy will receive concomitantly simvastatin and response will be monitored by paraprotein levels
Multiple Myeloma (MM) is an incurable haematological neoplasm that is characterized by
homing, survival, and proliferation of malignant, antibody producing plasma cells in the
bone marrow. All clinically relevant symptoms (cytopenia, hyperproteinemia and proteinuria
with renal insufficiency, hypercalcemia, osteolysis) are due to the aggressive infiltration
of the whole bone marrow by MM cells, while all other solid and lymphoid organs including
the peripheral blood are normally spared. From these clinical observations and from many
preclinical studies it is evident that adhesion of MM cells to the bone marrow cells
characterizes the biology of this disease. Adhesion of MM cells leads to the secretion of
stimulatory cytokines,upregulation of adhesion molecules, proliferation of MM cells, and
drug resistance.
Statins, like simvastatin, inhibit the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase, which catalyzes the conversion of HMG-CoA to mevalonate. Interestingly, in MM
models statins induce apoptosis, inhibit proliferation, overcome primary and secondary drug
resistance, and synergize with cytotoxic drugs. Oligonucleotide microarray analyses
demonstrated that de novo and acquired drug resistance are associated with an increase of
HMG-CoA reductase gene expression. We have shown before that adhesion of MM cells to bone
marrow stromal cells mediates strong multidrug resistance and that this can be overcome by
co-treatment with simvastatin in non-toxic concentrations. Interestingly, statin induced
apoptosis in MM cells is not hampered by adhesion to bone marrow stromal cells.
Based upon these comprehensive preclinical findings clinical trials to investigate the
in-vivo antimyeloma activity of statins are urgently needed. Our in vitro studies
demonstrated that inhibition of cell adhesion mediated drug resistance by simvastatin is
possible at low concentrations of about 1µM. We therefore suggested that cell adhesion
mediated drug resistance can be treated with approved doses of simvastatin (80mg daily).
Consequently we initiate a pilot phase II trial to investigate feasibility and clinical
effects of simvastatin concomitantly with chemotherapy as preparation for a randomized
trial.
As the primary goal is to prove the hypothesis that simvastatin can overcome drug resistance
in vivo only patients not responding to chemotherapy will be included. Chemotherapy is
defined as bortezomib and bendamustin, as both are effective and approved drugs in the
therapy of relapsed myeloma. Further inclusion criteria are age over 18 years, proven MM
(serum protein below 11g/dl, life expectancy > 3 months) and treatment indication with
measurable paraprotein. In the case of no change (paraprotein increase less than 25% and
paraprotein decline less than 50%) after two cycles of bortezomib (one cycle: 1.3 mg/m2
d1,4,8,11) or bendamustin (one cycle: 100 mg/m2 d1+2) the patients will receive two further
cycles with concomitant simvastatin treatment (80 mg daily starting two days before
chemotherapy and stopping two days after chemotherapy). Exclusion criteria are severe organ
failure and risk factors for rhabdomyolysis (untreated hypothyroidism, active liver disease,
terminal renal insufficiency, acute infectious disease, myopathy, heriditary myopathy in the
family history, alcohol abuse, comedication with itraconazole, ketoconazole, erythromycin,
clarithromycin, HIV protease inhibitors, nefazodone, cyclosporine, fibrates, niacin,
amiodarone, verapamil).
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |